Mobile Infirmary Performs First-In-Region Treatment

Infirmary Health’s Heart & Vascular Institute announced that Mobile Infirmary has become the first hospital in the region to utilize the newly U.S. Food and Drug Administration-approved AGENT Drug-Coated Balloon (DCB) by Boston Scientific for the treatment of coronary in-stent restenosis (ISR). ISR occurs when a previously placed coronary stent becomes narrowed again, limiting blood flow to the heart. The AGENT DCB offers a novel solution by delivering a therapeutic drug directly to the arterial wall during balloon angioplasty, without leaving a permanent implant behind. This approach reduces the risk of additional complications and preserves future treatment options. Dr. George Eyrich and Dr. Mina Jacob, interventional cardiologists with the Heart & Vascular Institute, successfully performed the first AGENT DCB procedures at Mobile Infirmary.

Read More

USA Health Hospitals Earn Leapfrog Group 2026 Full Transparency Badge

USA Health Hospitals Earn Leapfrog Group 2026 Full Transparency Badge

Cardiology Associates Welcomes Dr. Jared Mullins

Cardiology Associates Welcomes Dr. Jared Mullins

Mobile To Host Young Entrepreneur Showcase

Mobile To Host Young Entrepreneur Showcase

Mobile Community Workshop To Help Update DDD

Mobile Community Workshop To Help Update DDD

Baldwin Prep Expands Offerings

Baldwin Prep Expands Offerings

CACC Nursing Program Designated An Nln Center For Excellence

CACC Nursing Program Designated An Nln Center For Excellence

Dominguez & Persons Earns Position On Va Caribbean Construction MATOC

Dominguez & Persons Earns Position On Va Caribbean Construction MATOC

Thompson Holdings Appoints Todd Musterait To Board Of Directors

Thompson Holdings Appoints Todd Musterait To Board Of Directors

RTF Project Services Establishing Main Operations In Bay Minette

RTF Project Services Establishing Main Operations In Bay Minette

Subscribe to our weekly newsletter

Sign up here for free to get Bay Business News email newsletter every Friday.

By subscribing, you agree to our User Agreement and Privacy Policy & Cookie Statement.

Something went wrong. Please check your entries and try again.